4-(4-Aminobutoxy)aniline | 1613189-29-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(4-Aminobutoxy)aniline
• CAS: 1613189-29-9
• 化学式: C₁₀H₁₆N₂O
• 分子量: 180.25
• InChiKey: OQUPCBYIOAWJAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  61.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-Aminobutoxy)aniline 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 triethylamine tris(hydrogen fluoride) 、 sodium t-butanolate 作用下， 以 乙醇 、 异丙醇 、 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD

  摘要：

  A multivalent approach focused on amine-based secondary binding groups was applied to the discovery of long-acting inhaled beta(2)-agonists. Addition of amine moieties to the neutral secondary binding group of an existing beta(2)-agonist series was found to provide improved in vivo efficacy, but also led to the formation of biologically active aldehyde metabolites which were viewed as a risk for the development of these compounds. Structural simplification of the scaffold and blocking the site of metabolism to prevent aldehyde formation afforded a potent series of dibasic beta(2)-agonists with improved duration of action relative to their monobasic analogs. Additional optimization led to the discovery of 29 (TD-4306), a potent and selective beta(2)-agonist with potential for once-daily dosing. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.095
• 作为产物：
  描述：

  对氟硝基苯 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 作用下， 以 甲醇 、 二甲基亚砜 为溶剂， 生成 4-(4-Aminobutoxy)aniline
  参考文献：
  名称：

  Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD

  摘要：

  A multivalent approach focused on amine-based secondary binding groups was applied to the discovery of long-acting inhaled beta(2)-agonists. Addition of amine moieties to the neutral secondary binding group of an existing beta(2)-agonist series was found to provide improved in vivo efficacy, but also led to the formation of biologically active aldehyde metabolites which were viewed as a risk for the development of these compounds. Structural simplification of the scaffold and blocking the site of metabolism to prevent aldehyde formation afforded a potent series of dibasic beta(2)-agonists with improved duration of action relative to their monobasic analogs. Additional optimization led to the discovery of 29 (TD-4306), a potent and selective beta(2)-agonist with potential for once-daily dosing. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.095

文献信息

• NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION
  申请人：Sirigen II Limited

  公开号：EP3981819A2

  公开（公告）日：2022-04-13

  Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development of highly efficient biosensors. The invention further relates to the application of these polymers in assay methods.

  本文描述的是涉及中性共轭聚合物的方法、组合物和制造品，包括合成中性共轭水溶性聚合物的方法，该聚合物沿聚合物主链结构具有连接体和末端封端单元。这种聚合物可用于制造新型光电器件和开发高效生物传感器。本发明还涉及这些聚合物在检测方法中的应用。
• [EN] NOVEL REAGENTS FOR DIRECTED BIOMARKER SIGNAL AMPLIFICATION<br/>[FR] NOUVEAUX RÉACTIFS POUR L'AMPLIFICATION DIRIGÉE D'UN SIGNAL DE BIOMARQUEUR
  申请人：SIRIGEN INC

  公开号：WO2011091086A1

  公开（公告）日：2011-07-28

  Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development of highly efficient biosensors. The invention further relates to the application of these polymers in assay methods.